OptimizeRx (OPRX) Expected to Announce Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX - Get Free Report) is expected to be announcing its earnings results after the market closes on Wednesday, March 26th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $30.36 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

OptimizeRx Trading Down 1.8 %

OPRX stock traded down $0.16 during mid-day trading on Friday, hitting $8.63. 340,091 shares of the company were exchanged, compared to its average volume of 257,229. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $14.13. The firm has a market capitalization of $158.97 million, a P/E ratio of -6.49 and a beta of 1.31. The business has a fifty day simple moving average of $5.84 and a 200-day simple moving average of $5.94. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

Analysts Set New Price Targets

OPRX has been the subject of several research reports. Royal Bank of Canada reiterated a "sector perform" rating and issued a $6.00 target price (down previously from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. Lake Street Capital reaffirmed a "buy" rating and issued a $11.00 price objective on shares of OptimizeRx in a research note on Tuesday, December 24th. B. Riley raised OptimizeRx to a "strong-buy" rating in a research note on Wednesday, March 12th. Stephens assumed coverage on shares of OptimizeRx in a research note on Friday, December 20th. They set an "equal weight" rating and a $5.50 price target on the stock. Finally, JMP Securities reissued a "market outperform" rating and issued a $8.00 price objective on shares of OptimizeRx in a research note on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $9.06.

Remove Ads

Insider Activity

In other OptimizeRx news, Director James Paul Lang acquired 321,408 shares of the stock in a transaction dated Friday, March 14th. The stock was acquired at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the transaction, the director now owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.10% of the company's stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.